BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: de Mestier L, Zappa M, Hentic O, Vilgrain V, Ruszniewski P. Liver transarterial embolizations in metastatic neuroendocrine tumors. Rev Endocr Metab Disord. 2017;18:459-471. [PMID: 28975561 DOI: 10.1007/s11154-017-9431-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Ebbers SC, Braat AJAT, Moelker A, Stokkel MPM, Lam MGEH, Barentsz MW. Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial). Trials 2020;21:141. [PMID: 32024533 DOI: 10.1186/s13063-019-3888-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
2 de Mestier L, Lepage C, Baudin E, Coriat R, Courbon F, Couvelard A, Do Cao C, Frampas E, Gaujoux S, Gincul R, Goudet P, Lombard-Bohas C, Poncet G, Smith D, Ruszniewski P, Lecomte T, Bouché O, Walter T, Cadiot G; Thésaurus National de Cancérologie Digestive (TNCD). Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig Liver Dis 2020;52:473-92. [PMID: 32234416 DOI: 10.1016/j.dld.2020.02.011] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 10.5] [Reference Citation Analysis]
3 Huang J, Liu B, Lin M, Zhang X, Zheng Y, Xie X, Xu M, Xie X. Ultrasound-guided percutaneous radiofrequency ablation in treatment of neuroendocrine tumor liver metastases:a single-center experience. International Journal of Hyperthermia 2022;39:497-503. [DOI: 10.1080/02656736.2022.2048094] [Reference Citation Analysis]
4 de Ponthaud C, Menegaux F, Gaujoux S. Updated Principles of Surgical Management of Pancreatic Neuroendocrine Tumours (pNETs): What Every Surgeon Needs to Know. Cancers (Basel) 2021;13:5969. [PMID: 34885079 DOI: 10.3390/cancers13235969] [Reference Citation Analysis]
5 Clift AK, Frilling A. Liver-Directed Therapies for Neuroendocrine Neoplasms. Curr Oncol Rep 2021;23:44. [PMID: 33721122 DOI: 10.1007/s11912-021-01030-0] [Reference Citation Analysis]
6 Rindi G, Wiedenmann B. Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine. Nat Rev Endocrinol 2020;16:590-607. [PMID: 32839579 DOI: 10.1038/s41574-020-0391-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
7 Chen JX, Lin Y, Meng YL, Zhao AX, Huang XJ, Liang R, Li YQ, Liu ZH. Predicting the Survival Probability of Neuroendocrine Tumor Populations: Developing and Evaluating a New Predictive Nomogram. Biomed Res Int 2021;2021:9126351. [PMID: 33575356 DOI: 10.1155/2021/9126351] [Reference Citation Analysis]
8 Lee L, Ramos-Alvarez I, Jensen RT. Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies. Cancers (Basel) 2022;14:1250. [PMID: 35267558 DOI: 10.3390/cancers14051250] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Vullierme MP, Ruszniewski P, de Mestier L. Are recist criteria adequate in assessing the response to therapy in metastatic NEN? Rev Endocr Metab Disord 2021;22:637-45. [PMID: 33871762 DOI: 10.1007/s11154-021-09645-1] [Reference Citation Analysis]
10 Jin XF, Spampatti MP, Spitzweg C, Auernhammer CJ. Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important. Rev Endocr Metab Disord 2018;19:145-58. [PMID: 29464446 DOI: 10.1007/s11154-018-9443-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
11 Piron L, Cassinotto C, Guiu B. [Interventional radiology of liver tumors]. Presse Med 2019;48:1156-68. [PMID: 31672452 DOI: 10.1016/j.lpm.2019.10.010] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Werner RA, Solnes LB, Javadi MS, Weich A, Gorin MA, Pienta KJ, Higuchi T, Buck AK, Pomper MG, Rowe SP, Lapa C. SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework. J Nucl Med 2018;59:1085-91. [DOI: 10.2967/jnumed.117.206631] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
13 Ma ZY, Gong YF, Zhuang HK, Zhou ZX, Huang SZ, Zou YP, Huang BW, Sun ZH, Zhang CZ, Tang YQ, Hou BH. Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management. World J Gastroenterol 2020; 26(19): 2305-2322 [PMID: 32476795 DOI: 10.3748/wjg.v26.i19.2305] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 23] [Article Influence: 15.0] [Reference Citation Analysis]
14 Papamichail M, Pizanias M, Heaton ND, M P, M P, Nd H. Minimizing the risk of small-for-size syndrome after liver surgery. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00230-7. [PMID: 34961675 DOI: 10.1016/j.hbpd.2021.12.005] [Reference Citation Analysis]
15 Bajwa R, Madoff DC, Kishore SA. Embolotherapy for Hepatic Oncology: Current Perspectives and Future Directions. Dig Dis Interv 2020;4:134-47. [PMID: 32832829 DOI: 10.1055/s-0040-1712146] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Petersenn S, Koch CA. Neuroendocrine neoplasms – still a challenge despite major advances in clinical care with the development of specialized guidelines. Rev Endocr Metab Disord 2017;18:373-8. [DOI: 10.1007/s11154-018-9442-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]